Yiling Pharmaceutical Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shijiazhuang China (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2014
NCT02035644
First Marketed Drug
2007
amlodipine (norvasc)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BEIJING YILING | Boao Yiling Life Care Center | Conjupro Biotherapeutics | Conjupro Biotherapeutics, Inc. | Conupro Biotehrapeutics, and CSPC | CSPC Ouyi Pharmaceutical Co., Ltd. | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Shijiazhuang Yiling Pharmaceutical company, LTD | YILING | Yiling Pharmaceutical | Yiling Pharmaceutical Inc. | YILING PHARM LTD

Active Ingredients

Marketed Drugs (13)

aciclovir (zovirax) (2018)

amlodipine (norvasc) (2007)

anastrozole (arimidex) (2018)

buspirone (buspar) (2015)

celecoxib (celebrex) (2020)

ciprofloxacin (cipro) (2018)

felodipine (plendil) (2018)

lamotrigine (lamictal) (2021)

letrozole (femara) (2018)

lisinopril (zestril) (2020)

paroxetine (paxil) (2021)

sildenafil (viagra) (2012)

valaciclovir (Valtrex) (2020)

Drugs in Phase 4 Trials (4)

alendronic acid (fosamax) (1 trial)

alosetron (lotronex) (1 trial)

jinlida (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 3 Trials (15)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (5 trials)

cyclophosphamide (cytoxan) (5 trials)

Dexketoprofen (4 trials)

docetaxel (taxotere) (4 trials)

doxorubicin (Doxil) (6 trials)

gimeracil (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (4 trials)

paclitaxel (taxol) (16 trials)

pertuzumab (perjeta) (2 trials)

s-1 (1 trial)

tegafur (2 trials)

trastuzumab (herceptin) (3 trials)

tromethamine (tham) (4 trials)

Drugs in Phase 2 Trials (20)

acetylsalicylic acid (aspirin) (1 trial)

butylphthalide (1 trial)

cisplatin (platinol) (4 trials)

cpo107 (1 trial)

dexamethasone (1 trial)

epirubicin (ellence) (4 trials)

fluorouracil (efudex) (3 trials)

gemcitabine (gemzar) (5 trials)

irinotecan (Camptosar) (6 trials)

kt07 (2 trials)

lenalidomide (revlimid) (1 trial)

leucovorin (3 trials)

mitoxantrone (novantrone) (7 trials)

rituximab (rituxan) (2 trials)

sg001 (1 trial)

temozolomide (temodar) (1 trial)

triprizumab (1 trial)

venetoclax (venclexta) (1 trial)

vincristine (oncovin) (2 trials)

xy03-ea (1 trial)

Drugs in Phase 1 Trials (13)

amlodipine (norvasc) (1 trial)

cpo102 (1 trial)

etoposide (vepesid) (1 trial)

ha115 (1 trial)

levamlodipine (Conjupri) (1 trial)

phenlarmide (2 trials)

phentermine (wyamine) (1 trial)

prednisone (meticorten) (1 trial)

syhx 1901 (1 trial)

syhx2005 (1 trial)

syhx2011 (1 trial)

vinorelbine (navelbine) (1 trial)

xy0206 (2 trials)

Drugs in Other Trials (1)

pirarubicin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Asthma (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cognitive Dysfunction (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 4)

Epilepsy (Phase 2)

Hypertension (Phase 1)

Influenza, Human (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 1)

Sclerosis (Phase 2)

Stomach Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial APIs: 53